Swedish medical device company Acarix AB (FN STO:ACARIX) (OTCQB:ACIXF) announced on Monday that the CADScor System has received regulatory approval from the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP), clearing the way for commercial availability of the technology across the United Arab Emirates.

The company said that this approval marks Acarix's entry into the Gulf region, and extends the reach of the CADScor System, a point-of-care diagnostic aid that uses highly sensitive acoustics and advanced computational analysis and AI to assess coronary blood flow and rule out significant coronary artery disease (CAD) in patients presenting with chest pain or shortness of breath.

The system is designed to deliver a patient-specific result in under 10 minutes, supporting earlier risk stratification and reducing reliance on more invasive and costly downstream testing.

Acarix will bring the CADScor System to market in the UAE through its commercial partner, UniTech Solutions, which will lead distribution, clinical support, and account development across the region.